Acute effects of ketamine, quantified with PET and radioligand

Acute effects of ketamine on the glutamatergic NMDA receptor quantified by PET and the radioligand (R)-[11C]-Me-NB1 - Ketamine, acute effects

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2022-003266-21-AT

Enrollment

Registered

2022-12-05

Start date

2023-03-31

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute effects of ketamine

Interventions

Trade Name: Ketamin-hameln Product Name: (S)-Ketamin Product Code: 32265.00.00 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Ketamine Other descriptive name: Ketamine hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - General health based on medical history, physical examination and structured clinical interview for DSM-V (SCID) - Age 18 to 55 years - Willingness and competence to sign the informed consent form Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 55 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Current or history of psychiatric or neurological disease - Current medical illness requiring treatment - Current or former psychopharmacological treatment - Pregnancy or currently breastfeeding - Current or former substance abuse - Any contraindication for MRI e.g. (implants, stainless steel graft) - Failure to comply with the study protocol or to follow the instruction of the investigating team - If the radiation exposure by PET or SPECT or CT during scientific study participation in the last 10 years exceeds 30 mSv

Design outcomes

Primary

Measure	Time frame
Main Objective: Investigation of the acute effect of ketamine on the NMDA receptor using PET;Secondary Objective: Investigation of potential long-term effects on the NMDA receptor after ketamine administration ;Primary end point(s): Significant reduction of the volume distribution of the radioligand;Timepoint(s) of evaluation of this end point: Study session 1 and 2	—

Secondary

Measure	Time frame
Secondary end point(s): Investigate the alterations in GluN2B volume of distribution, depending on the time of placebo/ketamine administration;Timepoint(s) of evaluation of this end point: Study session 1 and 2	—

Countries

Austria

Contacts

Public ContactSponsor

Rupert Lanzenberger, Department of Psychiatry and Psychotherapy, Medical University of Vienna

rupert.lanzenberger@meduniwien.ac.at004314040035760

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026